ReviewHuman vaccines & immunotherapeutics2023
A review of technological developments in lipid nanoparticle application for mRNA vaccination.
Review in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 1 synthesis or guideline pooled it.
- A systematic review on vaccine developmental approaches: Evaluating efficacy, and addressing challenges of infectious diseases in the post-COVID-19 era.Virus research · 2026Pooled it
- Horizon Scanning Methods for Health Care Technology Innovation Identification: Rapid Scoping Review of Patent Research Studies.Interactive journal of medical research · 2025Review
- [Variants of biotechnological drugs in dermatology : Status quo and future].Dermatologie (Heidelberg, Germany) · 2024Article
- 7.10 MAG. A Novel Host Monoacylglyceride forCrystal growth & design · 2024Article
- Lipid Nanoparticle (LNP) Delivery Carrier-Assisted Targeted Controlled Release mRNA Vaccines in Tumor Immunity.Vaccines · 2024Review
- Cell Reprogramming and Differentiation Utilizing Messenger RNA for Regenerative Medicine.Journal of developmental biology · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticle (LNP) technology is critical to the advancement of mRNA vaccines. However, most studies focus on technical aspects and neglect the patent landscape. Moreover, there is a lack of differentiation of LNP technology differences among mRNA, mRNA vaccines, and COVID-19 mRNA vaccines, leading to confusing comparisons. This study fills this gap by analyzing LNP technology in academic journals and patents for mRNA, mRNA vaccines, and COVID-19 mRNA vaccines. The results show (1) academic impact on journal articles and patents, but no direct positive correlation; (2) the USA leads in academic research and patents, with China following closely; and (3) many cited articles have sponsors, indicating the importance of industry-university collaboration. This research aids strategic planning in government, academia, and industry, by providing trend analysis of LNP technology in journals and patents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.